News Releases

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 16, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported the grants of non-statutory stock options to four new employees in connection with

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 8, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting company at the Canaccord Genuity “Horizons in

Strong balance sheet: Approximately $110 million in cash and cash equivalents as of March 31, 2021 1 Company remains on-track for potential product approvals in US in August 2021 and in Europe in early 2022 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 7, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage

IND approval triggers $3 million milestone payment to Sesen Bio Product market application expected to be submitted to the National Medical Product s Administration in 2022 with potential approval in 2023 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 22, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 22, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported the grants of non-statutory stock options to three new employees in connection with

Strengthened balance sheet: $98 million in cash and cash equivalents as of February 28, 2021 1 Biologics License Application accepted by the FDA under Priority Review Marketing Authorization Application submitted in Europe with potential approval in early 2022   Company to host conference call at

Follows U.S. FDA acceptance of the Biologics License Application under Priority Review Potential approval in Europe anticipated in early 2022 Significant commercial opportunity in Europe with projected peak revenue of $450M-$1.1B CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 2, 2021-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that the Company will host a conference call with Dr.

FDA stated it is not currently planning to hold an advisory committee meeting Potential for Vicineum to be a best-in-class treatment with projected peak revenue of $1B-$3B globally, $400M-$900M in the US Company to hold conference call at 8am ET CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 12, 2021-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Dr. Thomas Cannell , President and CEO will host a conference call on Tuesday,